Vascular endothelial growth factor (VEGF) inhibitor could enhance antitumor immunity restored by PD-1/PD-L1 antibody by antagonizing the VEGF-mediated immunosuppressive effect within the tumor microenvironment [15, 16]. This evidence concerns the gene CD274 and neoplasm.